COMPASS Pathways plc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
United Kingdom
Business Address
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE, X0, WA14 2DT
Mailing Address
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE, X0, WA14 2DT
Phone
1-716-676-6461
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 10-K Annual financial report | March 24, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 19, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
Annual Reports
10-K
March 24, 2026
- Successful Phase 3 clinical trial results for COMP360 in treatment-resistant depression.
- Initiated rolling FDA submission process to potentially accelerate drug approval.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.